Charles Fuchs, MD: Bevacizumab Plus Chemotherapy
Why would you choose to add bevacizumab to a chemotherapy regimen?
The data are pretty compelling. You significantly add to the efficacy of standard chemotherapies by adding bevacizumab to chemotherapy. Moreover, the tolerability of adding bevacizumab is really exceptional. It adds very little in the way of toxicity, so in quality of life you lose nothing. Patients I think tolerate the antibody so well, and given its benefit, I would routinely add bevacizumab to first-line chemotherapy.
There are a few rare circumstances where you might not add bevacizumab, namely if there's a risk of perforation or if the patient has a fistula from the surgery, you wouldn't want to give bevacizumab within 4 weeks of surgery. So if you're starting chemotherapy shortly after surgery, you might delay adding bevacizumab until 4 weeks have transpired.
Unresectable Colon Cancer: Case 1
68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More
